Goldman Sachs issued a report, raising CSPC's net profit forecast from 2021 to 2023 by 7.6%, 4.2%, and 5.9% respectively., including the valuation of innovative drugs from 111 billion yuan to 85.9 billion yuan to reflect the impact of new drug price cuts, but the valuation of generic drugs has been raised from 24 billion yuan to 52 billion yuan, because as more new generic drugs gain market share through volume procurement, the growth prospects of related businesses will improve. While considering the price increase during the pandemic, API...
Web link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments